10x Genomics (NASDAQ:TXG) CFO Sells $225,872.00 in Stock

10x Genomics (NASDAQ:TXG) CFO Adam Taich sold 11,888 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the transaction, the chief financial officer owned 297,385 shares of the company’s stock, valued at $5,650,315. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

10x Genomics Trading Down 5.3%

NASDAQ TXG traded down $1.06 during trading hours on Tuesday, reaching $19.07. 5,111,169 shares of the company’s stock were exchanged, compared to its average volume of 3,246,832. The firm has a fifty day moving average of $13.55 and a 200-day moving average of $12.44. 10x Genomics has a one year low of $6.78 and a one year high of $20.34. The stock has a market cap of $2.41 billion, a PE ratio of -30.76 and a beta of 2.13.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. The company had revenue of $149.00 million for the quarter, compared to analyst estimates of $142.50 million. 10x Genomics had a negative return on equity of 11.50% and a negative net margin of 11.89%.The business’s revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. 10x Genomics has set its Q4 2025 guidance at EPS. As a group, research analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

TXG has been the subject of a number of research analyst reports. UBS Group boosted their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Canaccord Genuity Group increased their price target on shares of 10x Genomics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Barclays raised their price target on shares of 10x Genomics from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Zacks Research downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Finally, Piper Sandler raised their price target on 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, 10x Genomics currently has an average rating of “Hold” and an average target price of $14.88.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TXG. CIBC Bancorp USA Inc. bought a new stake in 10x Genomics in the third quarter valued at approximately $134,000. Jacobs Levy Equity Management Inc. boosted its position in shares of 10x Genomics by 22.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,947,989 shares of the company’s stock worth $34,462,000 after purchasing an additional 550,250 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of 10x Genomics by 14.9% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 25,365 shares of the company’s stock valued at $287,000 after buying an additional 3,296 shares during the period. XTX Topco Ltd grew its holdings in shares of 10x Genomics by 41.0% in the 3rd quarter. XTX Topco Ltd now owns 81,070 shares of the company’s stock valued at $948,000 after buying an additional 23,555 shares during the period. Finally, Voleon Capital Management LP increased its position in shares of 10x Genomics by 73.9% in the 3rd quarter. Voleon Capital Management LP now owns 306,101 shares of the company’s stock valued at $3,578,000 after buying an additional 130,094 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.